Temozolomide (TMZ), a common alkylating agent used in adjuvant chemotherapy for HGG, has been shown to upregulate the CXCL8-dependent CXCL2/CXCR2 axis, promoting angiogenesis and the recruitment of tumor-associated macrophages. The gene discussed is CXCL2; the disease is neoplasm.